Intravenous administration of muse cells improves cerebral ischemia outcome via immunomodulation in the spleen.

ABSTRACT: Ischemic stroke is a leading cause of disability and death globally. Stem cell therapies are emerging as a frontier for enhancing post-stroke recovery, with Muse cells-a subclass of pluripotent stem cells-demonstrating considerable promise. Muse cells are notable not only for their potential in cell replacement but also for their role in modulating immune responses following cerebral infarction. In the present study, we administered Muse cells intravenously to mice after inducing a stroke via distal middle cerebral artery occlusion. We evaluated motor outcomes, splenocyte populations, cytokine profiles, and gene expression 2 weeks after inducing stroke. Additionally, comparisons were drawn between outcomes in splenectomized mice and those receiving adoptive splenocyte transfer to discern t

SUBMITTER: Kato Y 

PROVIDER: S-EPMC11563515 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature